Clinics in Dermatology
Volume 25, Issue 1 , Pages 93-100 , January 2007

Peripheral arterial disease: diagnosis, treatment, and systemic implications

References 

  1. Levy PJ. Epidemiology and pathophysiology of peripheral arterial disease. Clin Cornerstone. 2002;4:1–15
  2. Selvin E, Erlinger TP. Prevalence and risk factors for peripheral arterial disease in the United States: results from the National Health and Examination Survey, 1999-2000. Circulation. 2004;110:738–743
  3. Newman AB, Sheamanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999;19:538–545
  4. Gey DC, Lesho EP, Manngold J. Management of peripheral arterial disease. Am Fam Physician. 2004;69:525–532
  5. Cimminiello C. PAD. Epidemiology and pathophysiology. Thromb Res. 2002;106:V295–V301
  6. Leibson CL, Ransom JE, Olson W, et al. Peripheral arterial disease, diabetes, and mortality. Diabetes Care. 2004;27:2843–2849
  7. Gutierrez J, de Dios Luna J, Linares J, et al. Relationship between peripheral arterial occlusive disease (PAOD) and chronic Chlamydophila (Chlamydia) pneumoniae infection. A meta-analysis. Thromb Haemost. 2005;93:1153–1160
  8. Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity and peripheral arterial disease. The San Diego Population Study. Circulation. 2005;112:2703–2707
  9. Feinglass J, Rucker-Whitaker C, Lindquist L, McCarthy WJ, Pearce WH. Racial differences in primary and repeat lower extremity amputation: results from a multihospital study. J Vasc Surg. 2005;41:823–829
  10. Imparato AM, Kim GF, Davidson T, Crowley JG. Intermittent claudication: its natural course. Surgery. 1975;78:795–799
  11. Rockson SG, Cooke JP. Peripheral arterial insufficiency: mechanisms, natural history, and therapeutic options. Adv Intern Med. 1998;43:253–277
  12. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386
  13. Long TH, Criqui MH, Vasilevskis EE, et al. The correlation between the severity of peripheral artery disease and carotid occlusive disease. Vasc Med. 1999;4:135–142
  14. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172–1181
  15. Caicoya Gomez-Moran M, Corrales Canel C, Lasheras Mayo C, et al. The association between a cerebrovascular accident and peripheral arterial disease: a case-control study in Asturias, Spain. Rev Clin Esp. 1995;195:830–835
  16. Tonelli C, Finzi G, Catamo A, et al. Prevalence and prognostic value of peripheral arterial disease in stroke patients. Int Angiol. 1993;12:342–343
  17. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119–128
  18. Dormandy JA, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999;12:142–147
  19. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  20. Jensen SA, Vatten LJ, Romundstad PR, Myhre HO. The prevalence of asymptomatic arterial obstruction in the lower extremities among men and women 60 to 69 years of age. Int Angiol. 2003;22:340–343
  21. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286:1599–1606
  22. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002;136:873–883
  23. McDermott MM, Criqui MH, Greenland P, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower extremity performance. J Vasc Surg. 2004;39:523–530
  24. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292:453–461
  25. McDermott MM, Greenland P, Guralnik JM, et al. Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease. J Gen Intern Med. 2003;18:461–467
  26. McGee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia: a critical review. Arch Intern Med. 1998;158:1357–1364
  27. Gathan V. The noninvasive vascular laboratory. Surg Clin North Am. 1998;78:507–518
  28. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109:733–799
  29. Barnes RW. Noninvasive diagnostic assessment of peripheral vascular disease. Circulation. 1991;83(Suppl. 2):20–27
  30. Portugaller HR, Schoellnast H, Hausegger KA, et al. Multislice spiral CT angiography in peripheral arterial occlusive disease: a valuable tool in detecting significant arterial narrowing?. Eur Radiol. 2004;14:1681–1687
  31. Koelemay MJ, Lijmer JG, Stoker J, Legemate DA, Bossuyt P. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. JAMA. 2001;285:1338–1345
  32. Rose SC. Noninvasive vascular laboratory for evaluation of peripheral arterial occlusive disease: Part II. Clinical applications: chronic usually atherosclerotic lower extremity ischemia. J Vasc Interv Radiol. 2000;11:1257–1275
  33. Nicholas GG, Myers JL, DeMuth WE. The role of vascular laboratory criteria in the selection of patients for lower extremity amputation. Ann Surg. 1982;195:469–473
  34. Carter SA. The relationship of distal systolic pressures to healing of skin lesions in limbs with arterial occlusive disease, with special reference to diabetes mellitus. Scand J Clin Lab Invest. 1973;31(Suppl):239–243
  35. Baker WH, Barnes RW. Minor forefoot amputations in patients with low ankle pressure. Am J Surg. 1977;133:331–332
  36. Holstein P, Noer I, Tonnesen KH, Sager P, Lassen NA. Distal blood pressure in severe arterial insufficiency: strain-gauge, radioisotopes, and other methods. In:  Bergan JJ,  Yao ST editor. Gangrene and severe ischemia of the lower extremities. New York: Grunes & Straton; 1978;p. 95–114
  37. Harward TRS, Volny J, Golbranson F, Bernstein EF, Fronek A. Oxygen inhalation–induced transcutaneous Po2 changes as a predictor of amputation level. J Vasc Surg. 1985;2:220–227
  38. Karanfilian RG, Lynch TG, Zirul VT, et al. The value of laser Doppler velocimetry and transcutaneous oxygen tension determination in predicting healing of ischemic forefoot ulceration and amputations in diabetic and nondiabetic patients. J Vasc Surg. 1986;4:511–516
  39. Ballard JL, Eke CC, Bunt TJ, Killeen JD. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. J Vasc Surg. 1995;22:485–492
  40. Okaa RK, Umoh E, Szuba A, Giacomini JC, Cooke JP. Suboptimal intensity of risk factor modification in PAD. Vasc Med. 2005;10:91–96
  41. Jonasson T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction, and mortality. Acta Med Scand. 1987;221:253–260
  42. Gordon T, Kannel WB, McGee D, Dawber TR. Death and coronary attacks in men after giving up cigarette smoking: a report from the Framingham Study. Lancet. 1974;2:1345–1348
  43. Schillinger M, Exner M, Mlekusch W, et al. Effect of smoking on restenosis during the 1st year after lower-limb endovascular interventions. Radiology. 2004;231:831–838
  44. Willigendael EM, Teijink JA, Bartelink ML, et al. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005;42:67–74
  45. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in pharmacotherapy of smoking. JAMA. 1999;281:72–76
  46. LaRosa JC, Jiang HE, Vuputurri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  47. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane review). In: Cochrane Library. Oxford, England: Update Software; 2001;
  48. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  49. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  50. Grodzinska L, Starzyk D, Bieron K, et al. Simvastatin effects in normo- and hypercholesterolemic patients with peripheral arterial occlusive disease: a pilot study. Basic Clin Pharmacol Toxicol. 2005;96:413–419
  51. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  52. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4–S36
  53. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure–lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955–1964
  54. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  55. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev. 1998;
  56. Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. J Am Board Fam Pract. 2001;14:443–450
  57. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxyfylline for treating intermittent claudication. Am J Med. 2000;109:523–530
  58. CAPRIE Steering Committee . A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–1339
  59. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337
  60. Ho V, Wirthlin D, Yun H, Allison J. Physician supply, treatment, and amputation rates for peripheral arterial disease. J Vasc Surg. 2005;42:81–87
  61. Serveri GGN, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25:1845–1852
  62. Violi F, Marubini E, Coccheri S, Nenci GG. Improvement of walking distance by defibrotide in patients with intermittent claudication—results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent Claudication Italian Study. Thromb Haemost. 2000;83:672–677
  63. Balzer K, Bechara G, Bisler H, et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. Int Angiol. 1991;10:229–232
  64. Anonymous . Two randomized and placebo-controlled studies of an oral prostacyclin analogue (iloprost) in severe leg ischaemia. The Oral Iloprost in Severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg. 2000;20:358–362
  65. Lievre M, Morand S, Besse B, Fiessinger J, Boissel J. Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication. A double-blind, randomized, multicenter controlled trial. Circulation. 2000;102:426–431
  66. Mohler ER, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue. A double-blinded, randomized, controlled trial. J Am Coll Cardiol. 2003;41:1679–1686
  67. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomized controlled prostaglandin E1} studies in peripheral arterial occlusive disease stages III and IV. Vasa. 2004;33:137–144
  68. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-l-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34:1618–1624
  69. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001;110:616–622
  70. Hiatt WR. Treatment of disability in peripheral arterial disease: new drugs. Curr Drug Targets—Cardiovasc Haematol Disord. 2004;4:227–231
  71. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol. 1994;23:S48–S52
  72. Bonvini R, Baumgartner I, Do do D, et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. J Am Coll Cardiol. 2003;41:409–412
  73. Zabakis P, Kardamakis DM, Siablis D, et al. External beam radiation therapy reduces the rate of re-stenosis in patients treated with femoral stenting: results of a randomized study. Radiother Oncol. 2005;74:11–16
  74. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE Investigators. Am Heart J. 2000;140:67–73
  75. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004;116:797–806
  76. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets. 2004;15:117–125
  77. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg. 2002;35:413–421
  78. Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation. 2002;105:2646–2652
  79. Vainas T, Stassen FR, Schurink GW, et al. Secondary prevention of atherosclerosis through Chlamydia pneumoniae eradication (SPacing Clin Electrophysiol trial): a randomized clinical trial in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2005;29:403–411
  80. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000;108:276–281
  81. Kim H-J, Jang SY, Park J-I, et al. Vascular endothelial growth factor–induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med. 2004;36:336–344
  82. Melillo G, Serino F, Cirielli C, Capogrossi MC. Gene therapy in peripheral artery disease. Curr Drug Targets—Cardiovasc Haematol Disord. 2004;4:295–300

PII: S0738-081X(06)00137-4

doi: 10.1016/j.clindermatol.2006.09.006

Clinics in Dermatology
Volume 25, Issue 1 , Pages 93-100 , January 2007

Article Tools